Transplant Immunology and Rejection

Understanding the immune system's response to transplanted tissue is critical to modern medicine's success. Organ transplantation is a life-saving procedure, but its success hinges entirely on managing the recipient's immune system, which is biologically wired to attack foreign material. This guide covers the classifications, mechanisms, and clinical management of transplant rejection and related conditions, a high-yield topic for medical studies and the MCAT.

Foundations: Immune Recognition of the Allograft

The central challenge in transplantation is that the recipient's immune system recognizes the donor organ—called an allograft—as foreign. This recognition primarily revolves on Human Leukocyte Antigens (HLAs), which are proteins present on the surface of nearly all nucleated cells. Think of HLAs as a unique cellular "barcode." A perfect match (only possible between identical twins) means the barcodes are identical, and the graft is seen as "self." In all other cases, the mismatched HLAs are seen as foreign antigens.

Immune recognition occurs via two primary pathways. In the direct pathway, recipient T cells directly recognize the mismatched donor HLA molecules on the surface of donor-derived "passenger" immune cells within the graft. This pathway is dominant in early rejection. In the indirect pathway, recipient antigen-presenting cells process donor HLA proteins and present them to recipient T cells, a process that becomes more important in chronic rejection. This initial recognition is the spark that can ignite the various types of rejection, categorized by their timing and effector mechanisms.

Hyperacute Rejection: The Immediate Attack

Hyperacute rejection is a catastrophic event that occurs within minutes to hours after the transplant's blood supply is reconnected. It is caused by preformed donor-specific antibodies in the recipient's circulation. These antibodies are typically the result of prior sensitization from events like blood transfusions, previous transplants, or pregnancies.

The mechanism is swift and destructive:

1. Preformed antibodies bind to donor HLA antigens on the endothelial cells lining the graft's blood vessels.
2. This binding activates the complement cascade, a powerful arm of the innate immune system.
3. Complement activation leads to formation of the membrane attack complex (MAC), which lyses endothelial cells.
4. Simultaneously, complement fragments promote inflammation, platelet aggregation, and widespread thrombosis (clotting).
5. The graft undergoes ischemic necrosis due to the occluded blood vessels and is irreversibly destroyed.

Clinically, the graft becomes mottled, cyanotic, and ceases to function immediately. This type of rejection is largely preventable by performing a crossmatch test before transplantation. This test mixes recipient serum with donor lymphocytes to detect preformed antibodies; a positive crossmatch is an absolute contraindication to proceeding with the transplant.

Acute Rejection: The Battleground of Weeks to Months

Acute rejection is the most common form of rejection and typically occurs within the first weeks to six months post-transplant, though it can happen later if immunosuppression is reduced. It is divided into two main types based on the primary immune effector involved: T cell-mediated and antibody-mediated.

Acute T Cell-Mediated Rejection (TCMR): This is a classic cell-mediated response. Recipient CD8+ cytotoxic T lymphocytes, activated via the direct pathway, infiltrate the graft and directly kill donor cells expressing foreign HLA. CD4+ helper T cells orchestrate the inflammation by recruiting macrophages. Biopsy findings show lymphocyte infiltration into the graft tissue (interstitium) and tubules (in kidney transplants). Treatment involves augmenting immunosuppression, often with a pulse of high-dose corticosteroids.

Acute Antibody-Mediated Rejection (AMR): This form is driven by newly formed donor-specific antibodies post-transplant. The antibodies bind to graft endothelium, activating complement (similar to hyperacute rejection, but slower). A key histological feature is capillaritis—inflammation of small capillaries—and the deposition of complement split product C4d. Management is more complex and may include plasmapheresis (to remove antibodies), intravenous immunoglobulin (IVIG), and powerful anti-B-cell agents like rituximab.

For the MCAT: A classic test scenario contrasts the speed and mechanism of hyperacute (preformed antibodies, complement) vs. acute (newly primed T cells or antibodies) rejection. Understanding that acute rejection is often treatable with increased immunosuppression is a key clinical point.

Chronic Rejection: The Insidious Long-Term Threat

Chronic rejection, now more accurately termed Chronic Allograft Dysfunction, develops over months to years and is the leading cause of long-term graft failure. Unlike acute rejection, it is not effectively reversed by current immunosuppressive drugs. Its pathology is characterized by progressive fibrosis (scarring) and distinctive vascular changes.

The blood vessels within the graft undergo intimal hyperplasia—a smooth muscle cell proliferation and thickening of the vessel wall—which narrows the lumen and reduces blood flow, leading to chronic ischemia. In kidney transplants, this manifests as arteriosclerosis; in heart transplants, it's cardiac allograft vasculopathy. The interstitial fibrosis slowly strangles the functional tissue.

The etiology is multifactorial, involving both immune and non-immune factors. The indirect pathway of allorecognition is believed to play a major role, as are repeated subclinical episodes of acute rejection, side effects of long-term immunosuppression (like calcineurin inhibitor toxicity), and non-immune factors like hypertension and diabetes. Management focuses on slowing progression by controlling these risk factors, as the fibrotic changes are largely permanent.

Graft-versus-Host Disease: When the Donor Attacks

Graft-versus-host disease (GVHD) is a mirror-image problem that occurs in the context of bone marrow or hematopoietic stem cell transplants. Here, the graft itself is immunocompetent (contains mature T cells), and the recipient (host) is immunocompromised. Donor T cells within the graft attack recipient tissues, recognizing host HLA as foreign.

GVHD requires three conditions: (1) a graft containing immunocompetent T cells, (2) a recipient who is immunologically disparate from the donor, and (3) a recipient who is unable to mount an effective response to eliminate the donor cells. It primarily affects the skin (causing a rash), liver (causing hepatitis), and gastrointestinal tract (causing severe diarrhea). Prevention involves careful HLA matching and removing T cells from the graft (T-cell depletion) or using immunosuppressive drugs post-transplant. It’s crucial to distinguish that in solid organ transplantation, we worry about host-versus-graft (rejection), while in bone marrow transplantation, the major concern is graft-versus-host (GVHD).

Common Pitfalls

1. Confusing Timing with Mechanism: Don't assume all early rejection is antibody-mediated or all late rejection is T-cell mediated. Hyperacute is always antibody-mediated (preformed). Acute can be T-cell or antibody-mediated. Chronic has complex mechanisms. Focus on the underlying immunology, not just the timeline.
2. Misunderstanding "Chronic Rejection": Students often think it's just a slower version of acute rejection. The key distinction is the pathology: fibrosis and vascular intimal hyperplasia versus the cellular infiltrates and acute inflammation seen in acute rejection. Chronic rejection is a scarring process.
3. Mixing Up GVHD and Rejection: This is a fundamental directional error. Use this mnemonic: In solid organ Rejection, the Recipient's immune system attacks the Rightful (donor) tissue. In GVHD, the Graft attacks the Host.
4. Overlooking the Crossmatch: A common exam trap is presenting a scenario of hyperacute rejection and asking for the cause, with the correct answer being "failure to perform a pre-transplant crossmatch." The treatment for hyperacute rejection is prevention.

Summary

• Transplant rejection is classified by timing, mechanism, and histopathology. Hyperacute rejection (minutes/hours) is driven by preformed donor-specific antibodies activating complement, leading to thrombosis and necrosis.
• Acute rejection (weeks/months) can be T cell-mediated (lymphocyte infiltration) or antibody-mediated (new antibodies, C4d deposition) and is often treatable with intensified immunosuppression.
• Chronic rejection (months/years) involves progressive fibrosis and vascular intimal hyperplasia, has mixed immune/non-immune causes, and is a major cause of long-term graft loss.
• Graft-versus-host disease is a distinct condition where immunocompetent donor T cells attack recipient tissues, primarily occurring after bone marrow transplantation.
• Clinical management hinges on prevention (crossmatching), prophylaxis (immunosuppression), and timely diagnosis (biopsy) to guide targeted treatment.